GMAB – Genmab A/S

Genmab A/S

GMAB

$32.78

Name : Genmab A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $20,177,604,608.00

EPSttm : 1.93

Genmab A/S

$32.78

1.59%

$0.53

Float Short %

0.57

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

-0.15

EPS Last/This Y

-0.03

EPS This/Next Y

-0.21

Price

33.34

Target Price

33.64

Analyst Recom

1.69

Performance Q

56.75

Relative Volume

3.14

Beta

0.96

Ticker: GMAB

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-08	GMAB	27.55	0.30	0.75	1957
2025-09-09	GMAB	27.84	0.30	0.21	1958
2025-09-10	GMAB	27.72	0.34	0.07	2014
2025-09-11	GMAB	28.63	0.34	0.06	2019
2025-09-12	GMAB	27.81	0.34	0.06	2003
2025-09-15	GMAB	27.99	0.34	0.78	2002
2025-09-16	GMAB	28.22	0.34	0.00	2013
2025-09-17	GMAB	28.08	0.34152823920266	0	2019
2025-09-18	GMAB	28.04	0.34	0.19	2020
2025-09-19	GMAB	28.28	0.34	0.00	1985
2025-09-22	GMAB	28.6	0.34	0.10	1797
2025-09-23	GMAB	28.74	0.34	0.12	1798
2025-09-24	GMAB	29.45	0.34	0.56	1830
2025-09-25	GMAB	28.84	0.34	3.33	1843
2025-09-26	GMAB	29.11	0.33	0.00	1832
2025-09-29	GMAB	29.33	0.33	0.01	1838
2025-09-30	GMAB	30.66	0.32	0.00	1853
2025-10-01	GMAB	31.77	0.31	0.30	1901
2025-10-02	GMAB	32.12	0.32	0.63	2089
2025-10-03	GMAB	33.56	0.34	0.04	2140
2025-10-06	GMAB	33.3	0.30	0.01	2373
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-08	GMAB	27.54	58.3	168.4	1.68
2025-09-09	GMAB	27.85	58.3	200.6	1.68
2025-09-10	GMAB	27.72	58.3	168.0	1.68
2025-09-11	GMAB	28.61	58.3	219.0	1.68
2025-09-12	GMAB	27.81	58.3	107.1	1.68
2025-09-15	GMAB	27.99	58.3	142.8	1.68
2025-09-16	GMAB	28.24	58.3	182.1	1.68
2025-09-17	GMAB	28.08	58.3	174.9	1.68
2025-09-18	GMAB	28.05	58.3	175.1	1.68
2025-09-19	GMAB	28.28	58.3	183.6	1.68
2025-09-22	GMAB	28.60	58.3	179.8	1.68
2025-09-23	GMAB	28.74	58.3	181.7	1.68
2025-09-24	GMAB	29.46	58.3	197.6	1.68
2025-09-25	GMAB	28.84	58.3	114.9	1.68
2025-09-26	GMAB	29.07	58.3	203.5	1.68
2025-09-29	GMAB	29.33	58.3	235.2	1.68
2025-09-30	GMAB	30.66	58.3	300.5	1.68
2025-10-01	GMAB	31.77	56.8	268.1	1.67
2025-10-02	GMAB	32.04	56.8	156.8	1.67
2025-10-03	GMAB	33.57	56.8	232.3	1.67
2025-10-06	GMAB	33.34	56.8	219.2	1.67
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-08	GMAB	0	-0.21	0.56
2025-09-09	GMAB	0	-0.21	0.56
2025-09-10	GMAB	0	-0.21	0.56
2025-09-11	GMAB	0	-0.21	0.63
2025-09-12	GMAB	0	-0.21	0.63
2025-09-15	GMAB	0	-0.20	0.63
2025-09-16	GMAB	0	-0.20	0.63
2025-09-17	GMAB	0	-0.20	0.63
2025-09-18	GMAB	0	-0.20	0.63
2025-09-19	GMAB	0	-0.20	0.63
2025-09-22	GMAB	0	-0.26	0.63
2025-09-23	GMAB	0	-0.26	0.63
2025-09-24	GMAB	0	-0.26	0.63
2025-09-25	GMAB	0	-0.26	0.57
2025-09-26	GMAB	0	-0.26	0.57
2025-09-29	GMAB	0	-0.26	0
2025-09-30	GMAB	0	-0.26	0.57
2025-10-01	GMAB	0	-0.26	0.57
2025-10-02	GMAB	0	-0.26	0.57
2025-10-03	GMAB	0	-0.26	0.57
2025-10-06	GMAB	0	-0.19	0.57
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.54

Avg. EPS Est. Current Quarter

0.45

Avg. EPS Est. Next Quarter

0.39

Insider Transactions

Institutional Transactions

-0.19

Beta

0.96

Average Sales Estimate Current Quarter

6217

Average Sales Estimate Next Quarter

6651

Fair Value

33.86

Quality Score

100

Growth Score

Sentiment Score

100

Actual DrawDown %

32.1

Max Drawdown 5-Year %

-63.1

Target Price

33.64

P/E

16.63

Forward P/E

19.23

PEG

1.66

P/S

6.05

P/B

3.86

P/Free Cash Flow

20.4

EPS

Average EPS Est. Cur. Y

1.67

EPS Next Y. (Est.)

1.46

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

37.52

Relative Volume

3.14

Return on Equity vs Sector %

-1.9

Return on Equity vs Industry %

11.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.06

EBIT Estimation

219.2

Genmab A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 2639

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

stock quote shares GMAB – Genmab A/S Stock Price stock today

news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch GMAB – Genmab A/S yahoo finance google finance

stock history GMAB – Genmab A/S invest stock market

stock prices GMAB premarket after hours

ticker GMAB fair value insiders trading

NVO – Novo Nordisk A/S

Novo Nordisk A/S

NVO

$59.26

Name : Novo Nordisk A/S

Sector : Healthcare

Industry: Drug Manufacturers - General

Mark. Cap: $267,614,748,672.00

EPSttm : 3.92

Novo Nordisk A/S

$59.26

0.66%

$0.395

Float Short %

0.85

Margin Of Safety %

Put/Call OI Ratio

0.76

EPS Next Q Diff

5.24

EPS Last/This Y

20.38

EPS This/Next Y

1.27

Price

59.67

Target Price

70.75

Analyst Recom

2.03

Performance Q

-14.35

Relative Volume

0.78

Beta

0.65

Ticker: NVO

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-08	NVO	54.27	0.80	0.51	1152827
2025-09-09	NVO	54.15	0.80	0.52	1165607
2025-09-10	NVO	54.38	0.80	0.45	1183664
2025-09-11	NVO	54.29	0.80	0.78	1196762
2025-09-12	NVO	54.93	0.81	0.72	1211637
2025-09-15	NVO	55.88	0.78	0.50	1175035
2025-09-16	NVO	57.2	0.79	0.68	1188229
2025-09-17	NVO	58.2	0.79439609236234	0.29750971542094	1212294
2025-09-18	NVO	61.84	0.79	0.44	1222957
2025-09-19	NVO	61.56	0.80	0.53	1245598
2025-09-22	NVO	60.74	0.78	0.43	1059152
2025-09-23	NVO	59.44	0.77	0.55	1085469
2025-09-24	NVO	58.74	0.76	0.39	1102228
2025-09-25	NVO	56.08	0.77	0.95	1116257
2025-09-26	NVO	55.6	0.79	0.92	1163659
2025-09-29	NVO	55.5	0.81	0.53	1166471
2025-09-30	NVO	55.41	0.80	0.63	1226165
2025-10-01	NVO	59.11	0.79	0.26	1257392
2025-10-02	NVO	58.74	0.78	0.46	1300567
2025-10-03	NVO	59.6	0.78	0.35	1337653
2025-10-06	NVO	59.71	0.76	0.31	1292418
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-08	NVO	54.28	-3.7	-490.8	24.84
2025-09-09	NVO	54.30	-3.7	-292.8	24.84
2025-09-10	NVO	54.38	-3.7	270.0	24.84
2025-09-11	NVO	54.30	-3.7	-553.7	24.84
2025-09-12	NVO	54.92	-3.7	-281.7	24.84
2025-09-15	NVO	55.61	-12.8	740.4	24.43
2025-09-16	NVO	57.20	-12.8	588.3	24.43
2025-09-17	NVO	58.19	-12.8	724.4	24.43
2025-09-18	NVO	61.84	-12.8	1475.1	24.23
2025-09-19	NVO	61.40	-12.8	-68.6	24.23
2025-09-22	NVO	60.71	-12.8	-95.7	24.28
2025-09-23	NVO	59.53	-12.8	-221.5	24.28
2025-09-24	NVO	58.73	-12.8	-75.6	24.28
2025-09-25	NVO	56.04	-12.8	-921.8	24.28
2025-09-26	NVO	55.61	-12.8	-474.6	24.28
2025-09-29	NVO	55.51	-12.8	268.9	24.28
2025-09-30	NVO	55.49	-12.8	68.2	24.28
2025-10-01	NVO	59.17	-19.6	2004.6	23.93
2025-10-02	NVO	58.77	-19.6	-	23.93
2025-10-03	NVO	59.64	-19.5	-	23.94
2025-10-06	NVO	59.67	-28.3	-269.7	23.94
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-08	NVO	0	-5.12	0.62
2025-09-09	NVO	0	-5.12	0.62
2025-09-10	NVO	0	-5.12	0.62
2025-09-11	NVO	0	-5.12	0.77
2025-09-12	NVO	0	-5.12	0.77
2025-09-15	NVO	0	-5.67	0.77
2025-09-16	NVO	0	-5.67	0.77
2025-09-17	NVO	0	-5.67	0.77
2025-09-18	NVO	0	-5.67	0.77
2025-09-19	NVO	0	-5.67	0.77
2025-09-22	NVO	0	-5.63	0.77
2025-09-23	NVO	0	-5.63	0.77
2025-09-24	NVO	0	-5.63	0.77
2025-09-25	NVO	0	-5.63	0.85
2025-09-26	NVO	0	-5.63	0.85
2025-09-29	NVO	0	-6.22	0.85
2025-09-30	NVO	0	-6.22	0.85
2025-10-01	NVO	0	-6.22	0.85
2025-10-02	NVO	0	-6.22	0.85
2025-10-03	NVO	0	-6.22	0.85
2025-10-06	NVO	0	-1.45	0.85
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.97

Avg. EPS Est. Current Quarter

4.92

Avg. EPS Est. Next Quarter

6.21

Insider Transactions

Institutional Transactions

-1.45

Beta

0.65

Average Sales Estimate Current Quarter

76582

Average Sales Estimate Next Quarter

81484

Fair Value

61.69

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

59.7

Max Drawdown 5-Year %

-68.5

Target Price

70.75

P/E

16.43

Forward P/E

14.5

PEG

1.37

P/S

4.42

P/B

10.02

P/Free Cash Flow

21.16

EPS

3.63

Average EPS Est. Cur. Y

23.94

EPS Next Y. (Est.)

25.22

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

35.6

Relative Volume

0.78

Return on Equity vs Sector %

Return on Equity vs Industry %

32.4

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.89

EBIT Estimation

-269.7

Novo Nordisk A/S

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 78387

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

stock quote shares NVO – Novo Nordisk A/S Stock Price stock today

news today NVO – Novo Nordisk A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch NVO – Novo Nordisk A/S yahoo finance google finance

stock history NVO – Novo Nordisk A/S invest stock market

stock prices NVO premarket after hours

ticker NVO fair value insiders trading

ASND – Ascendis Pharma A/S

Ascendis Pharma A/S

ASND

$208.70

Name : Ascendis Pharma A/S

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $12,637,705,216.00

EPSttm : -5.33

Ascendis Pharma A/S

$208.70

1.01%

$2.13

Float Short %

3.81

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.9

EPS Last/This Y

5.16

EPS This/Next Y

5.34

Price

211.2

Target Price

244.05

Analyst Recom

Performance Q

25.37

Relative Volume

1.82

Beta

0.43

Ticker: ASND

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-08	ASND	205.52	0.93	0.35	9918
2025-09-09	ASND	202.84	0.94	0.46	9924
2025-09-10	ASND	198.73	0.97	0.33	10164
2025-09-11	ASND	197.47	0.98	0.05	10149
2025-09-12	ASND	195.52	0.98	0.64	10141
2025-09-15	ASND	196.84	0.98	8.73	10140
2025-09-16	ASND	197.27	1.04	5.50	10438
2025-09-17	ASND	199.59	0.997273081418	0.64320388349515	10254
2025-09-18	ASND	199.35	0.97	0.80	10881
2025-09-19	ASND	197.82	0.96	0.45	11028
2025-09-22	ASND	196.58	0.46	0.38	8336
2025-09-23	ASND	193.81	0.44	4.42	8635
2025-09-24	ASND	193.27	0.45	0.00	8757
2025-09-25	ASND	189.69	0.40	0.02	9461
2025-09-26	ASND	191.61	0.40	0.31	9441
2025-09-29	ASND	191.57	0.39	0.16	9550
2025-09-30	ASND	198.84	0.40	0.02	9556
2025-10-01	ASND	204.23	0.39	0.02	9596
2025-10-02	ASND	201.2	0.39	0.46	9627
2025-10-03	ASND	204.15	0.41	0.09	9996
2025-10-06	ASND	211.01	0.41	0.12	10009
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-08	ASND	205.22	84.3	420.6	-2.46
2025-09-09	ASND	202.82	83.5	418.9	-2.51
2025-09-10	ASND	198.46	83.5	416.9	-2.51
2025-09-11	ASND	197.67	83.5	420.6	-2.51
2025-09-12	ASND	195.57	83.5	419.2	-2.51
2025-09-15	ASND	194.62	83.5	58.6	-2.51
2025-09-16	ASND	197.24	83.5	426.2	-2.51
2025-09-17	ASND	199.43	83.5	425.8	-2.51
2025-09-18	ASND	199.21	83.5	423.1	-2.51
2025-09-19	ASND	197.70	83.5	422.0	-2.51
2025-09-22	ASND	196.42	83.5	422.4	-2.51
2025-09-23	ASND	194.02	83.5	421.4	-2.51
2025-09-24	ASND	193.28	83.5	423.3	-2.51
2025-09-25	ASND	189.74	83.5	420.3	-2.51
2025-09-26	ASND	191.99	83.5	426.7	-2.51
2025-09-29	ASND	191.54	83.5	423.8	-2.51
2025-09-30	ASND	198.90	83.5	432.2	-2.51
2025-10-01	ASND	204.18	83.5	430.0	-2.51
2025-10-02	ASND	201.04	83.5	421.3	-2.51
2025-10-03	ASND	204.01	83.5	427.6	-2.51
2025-10-06	ASND	211.20	83.5	435.1	-2.51
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-08	ASND	0.00	-5.02	4.14
2025-09-09	ASND	0.00	-5.02	4.14
2025-09-10	ASND	0.00	-5.02	4.14
2025-09-11	ASND	0.00	-5.02	4.46
2025-09-12	ASND	0.00	-5.02	4.46
2025-09-15	ASND	0.00	-5.01	4.46
2025-09-16	ASND	0.00	-5.01	4.46
2025-09-17	ASND	0.00	-5.01	4.46
2025-09-18	ASND	0.00	-5.01	4.46
2025-09-19	ASND	0.00	-5.01	4.46
2025-09-22	ASND	0.00	-5.07	4.46
2025-09-23	ASND	0.00	-5.07	4.46
2025-09-24	ASND	0.00	-5.07	4.46
2025-09-25	ASND	0.00	-5.07	3.81
2025-09-26	ASND	0.00	-5.07	3.81
2025-09-29	ASND	0.00	-5.05	3.81
2025-09-30	ASND	0.00	-5.05	3.81
2025-10-01	ASND	0.00	-5.05	3.81
2025-10-02	ASND	0.00	-5.05	3.81
2025-10-03	ASND	0.00	-5.05	3.81
2025-10-06	ASND	0.00	-3.59	3.81
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.93

Avg. EPS Est. Current Quarter

-0.28

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

Institutional Transactions

-3.59

Beta

0.43

Average Sales Estimate Current Quarter

209

Average Sales Estimate Next Quarter

261

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

-1.5

Max Drawdown 5-Year %

-61.7

Target Price

244.05

P/E

Forward P/E

49.76

PEG

P/S

23.88

P/B

P/Free Cash Flow

EPS

-4.97

Average EPS Est. Cur. Y

-2.51

EPS Next Y. (Est.)

2.83

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-54.94

Relative Volume

1.82

Return on Equity vs Sector %

119.5

Return on Equity vs Industry %

133.1

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.05

EBIT Estimation

435.1

Ascendis Pharma A/S

Sector: Healthcare

Industry: Biotechnology

Employees: 1017

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today

news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025

marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance

stock history ASND – Ascendis Pharma A/S invest stock market

stock prices ASND premarket after hours

ticker ASND fair value insiders trading

GMAB – Genmab A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: GMAB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

NVO – Novo Nordisk A/S

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NVO

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y